These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28783977)

  • 1. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
    Matera R; Saif MW
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging cell-cycle inhibitors for pancreatic cancer therapy.
    Bayraktar S; Rocha Lima CM
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):571-82. PubMed ID: 23126234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
    Samore WR; Gondi CS
    Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced stage pancreatic cancer: novel therapeutic options.
    Saif MW
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for advanced pancreatic cancer: a review.
    Warsame R; Grothey A
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1327-36. PubMed ID: 23176620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
    Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer: a review of emerging therapies.
    Rosenberg L
    Drugs; 2000 May; 59(5):1071-89. PubMed ID: 10852640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
    Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
    Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-gene signaling pathways in pancreatic cancer.
    Drakaki A; Iliopoulos D
    Biomed J; 2013; 36(5):200-8. PubMed ID: 24225187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma.
    Yee NS; Kazi AA; Yee RK
    Curr Clin Pharmacol; 2015; 10(4):256-66. PubMed ID: 26548903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma.
    Quinn BA; Lee NA; Kegelman TP; Bhoopathi P; Emdad L; Das SK; Pellecchia M; Sarkar D; Fisher PB
    Adv Cancer Res; 2015; 127():283-306. PubMed ID: 26093904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab: still an option in the treatment of pancreatic cancer?
    Faloppi L; Andrikou K; Cascinu S
    Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers.
    Kim EJ; Semrad TJ; Bold RJ
    Expert Opin Investig Drugs; 2015 Jun; 24(6):781-94. PubMed ID: 25809274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer.
    Ding XZ; Tong WG; Adrian TE
    Pancreatology; 2001; 1(4):291-9. PubMed ID: 12120207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal biology and therapy in pancreatic cancer: a changing paradigm.
    Neesse A; Algül H; Tuveson DA; Gress TM
    Gut; 2015 Sep; 64(9):1476-84. PubMed ID: 25994217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.